Nationwide German Multicenter Study on the Prevalence of Antibiotic Resistance in Streptococcal Blood Isolates from Neutropenic Patients and Comparative in Vitro Activities of Quinupristin-dalfopristin and Eight Other Antimicrobials

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2001 Apr 28

PMID 11326015

Citations 2

Authors

R R Reinert

C von Eiff

M Kresken

J Brauers

D Hafner

A Al-Lahham

H SCHORN

R Lutticken

G Peters

Affiliations

Soon will be listed here.

Abstract

In a prospective multicenter study (1996 to 1999), 156 episodes of bacteremic streptococcal infections of neutropenic patients were evaluated. Streptococcus oralis (26.3%), S. pneumoniae (26.3%), S. agalactiae (11.5%), S. mitis (9%), and S. pyogenes (5.8%) were the predominant species. Four strains (2.6%) were found to be intermediately resistant to penicillin. One strain (0.6%) was found to be highly resistant to penicillin (MIC, 8 mg/liter). Reduced susceptibility to penicillin was detected among S. oralis (14.6%), S. mitis (7.1%), and S. pneumoniae (4.9%) isolates but was not recorded among S. agalactiae and S. pyogenes. Resistance rates and intermediate resistance rates for other antimicrobials were as follows (all species): amoxicillin, 1.3 and 3.2%; erythromycin, 16 and 2.6%; clindamycin, 5.8 and 0%; ciprofloxacin, 1.9 and 7.7%. Quinupristin-dalfopristin showed good in vitro activity against most streptococcal isolates (MIC at which 50% of the isolates were inhibited [MIC(50)], 0.5 mg/liter; MIC(90), 1 mg/liter, MIC range, 0.25 to 4 mg/liter).

Citing Articles

Species-specific difference in antimicrobial susceptibility among viridans group streptococci.

Chun S, Huh H, Lee N Ann Lab Med. 2015; 35(2):205-11.

PMID: 25729722 PMC: 4330170. DOI: 10.3343/alm.2015.35.2.205.

Alternative strategies for proof-of-principle studies of antibacterial agents.

Dalhoff A, Weintraub A, Nord C Antimicrob Agents Chemother. 2014; 58(8):4257-63.

PMID: 24867989 PMC: 4136043. DOI: 10.1128/AAC.02473-14.

References

McWhinney P, Patel S, Whiley R, Hardie J, Gillespie S, Kibbler C . Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother. 1993; 37(11):2493-5. PMC: 192417. DOI: 10.1128/AAC.37.11.2493. View

Podbielski A, Melzer B, Lutticken R . Application of the polymerase chain reaction to study the M protein(-like) gene family in beta-hemolytic streptococci. Med Microbiol Immunol. 1991; 180(4):213-27. DOI: 10.1007/BF00215250. View

Doern G, Ferraro M, Brueggemann A, Ruoff K . Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 1996; 40(4):891-4. PMC: 163225. DOI: 10.1128/AAC.40.4.891. View

Reinert R, Queck A, Kaufhold A, Kresken M, Lutticken R . Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992-1994. Clin Infect Dis. 1995; 21(6):1398-401. DOI: 10.1093/clinids/21.6.1398. View

von Eiff C, Peters G . In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci. Zentralbl Bakteriol. 1996; 283(4):497-501. DOI: 10.1016/s0934-8840(96)80127-7. View

Sutcliffe J, Tait-Kamradt A, Wondrack L . Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996; 40(8):1817-24. PMC: 163423. DOI: 10.1128/AAC.40.8.1817. View

Reinert R, Kaufhold A, Schlaeger J, Mechery V, Lutticken R . Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae isolates causing systemic infections among children in Germany, 1992 to 1996. Pediatr Infect Dis J. 1997; 16(2):244-5. DOI: 10.1097/00006454-199702000-00014. View

Altschul S, Madden T, Schaffer A, Zhang J, Zhang Z, Miller W . Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25(17):3389-402. PMC: 146917. DOI: 10.1093/nar/25.17.3389. View

Pfaller M, Jones R, Marshall S, Edmond M, Wenzel R . Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis. 1998; 29(4):259-63. DOI: 10.1016/s0732-8893(97)00159-4. View

10.

Rubinstein E, Bompart F . Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimicrob Chemother. 1997; 39 Suppl A:139-43. DOI: 10.1093/jac/39.suppl_1.139. View

11.

Konig A, Reinert R, Hakenbeck R . Streptococcus mitis with unusually high level resistance to beta-lactam antibiotics. Microb Drug Resist. 1998; 4(1):45-9. DOI: 10.1089/mdr.1998.4.45. View

12.

Jones R, Ballow C, Biedenbach D, DEINHART J, Schentag J . Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998; 31(3):437-51. DOI: 10.1016/s0732-8893(98)80002-3. View

13.

Felmingham D, Brown D, Soussy C . European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. Diagn Microbiol Infect Dis. 1998; 31(4):563-71. DOI: 10.1016/s0732-8893(98)00053-4. View

14.

Reinert R, Kresken M, Mechery V, Lemperle M, Lutticken R . In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 1998; 17(9):662-5. DOI: 10.1007/BF01708352. View

15.

Patrick C . Viridans streptococcal infections in patients with neutropenia. Pediatr Infect Dis J. 1999; 18(3):280-1. DOI: 10.1097/00006454-199903000-00016. View

16.

Wisplinghoff H, Reinert R, Cornely O, Seifert H . Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol. 1999; 37(6):1876-80. PMC: 84975. DOI: 10.1128/JCM.37.6.1876-1880.1999. View

17.

Maschmeyer G . Interventional antimicrobial therapy in febrile neutropenic patients. Diagn Microbiol Infect Dis. 1999; 34(3):205-12. DOI: 10.1016/s0732-8893(99)00024-3. View

18.

McCullers J, English B, Novak R . Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis. 1999; 181(1):369-73. DOI: 10.1086/315216. View

19.

Kugler K, Denys G, Wilson M, Jones R . Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2000; 36(4):269-72. DOI: 10.1016/s0732-8893(00)00111-5. View

20.

Carratala J, Gudiol F . Changing epidemiology of bacterial infection in neutropenic patients with cancer. Antibiot Chemother (1971). 2000; 50:1-9. View